Skip to main content
Premium Trial:

Request an Annual Quote

Bactobio Raises £6M in Private Financing

NEW YORK — Bactobio, a UK-based antimicrobial discover company, said on Monday that it has raised £6 million ($7.3 million) through an oversubscribed bridge financing round.

The round was led by Bridford Group with participation from angel investors Peder Holk Nielsen and Hugh Grant, as well as new investors.

Bactobio said it will use the funding to advance its bacteria-based compound discovery pipeline, which combines synthetic biology, next-generation sequencing, and machine learning to enable the characterization of next-generation antimicrobials.

"It is estimated that fewer than 3 percent of the potential natural products encoded in nature have been identified to date," Bactobio CSO Mark Wilkinson said in a statement. "Bactobio's bioactivity-driven but target-agnostic approach lets nature do the work and lead us towards compounds which have been unimaginable and previously inaccessible to drug-discovery efforts. Funds from this round will allow us to dig deeper into this previously untapped bioresource."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.